{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:55:08Z","timestamp":1795161308640,"version":"4.10.3"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic drugs that have shown improvement in renal and cardiovascular outcomes in patients with kidney disease, with and without diabetes. In this review, we will describe the different proposed mechanisms of action of SGLT2i. Gliflozins inhibit renal glucose reabsorption by blocking the SGLT2 cotransporters in the proximal tubules and causing glucosuria. This reduces glycemia and lowers HbA<jats:sub>1c<\/jats:sub> by ~1.0%. The accompanying sodium excretion reverts the tubuloglomerular feedback and reduces intraglomerular pressure, which is central to the nephroprotective effects of SGLT2i. The caloric loss reduces weight, increases insulin sensitivity, lipid metabolism, and likely reduces lipotoxicity. Metabolism shifts toward gluconeogenesis and ketogenesis, thought to be protective for the heart and kidneys. Additionally, there is evidence of a reduction in tubular cell glucotoxicity through reduced mitochondrial dysfunction and inflammation. SGLT2i likely reduce kidney hypoxia by reducing tubular energy and oxygen demand. SGLT2i improve blood pressure through a negative sodium and water balance and possibly by inhibiting the sympathetic nervous system. These changes contribute to the improvement of cardiovascular function and are thought to be central in the cardiovascular benefits of SGLT2i. Gliflozins also reduce hepcidin levels, improving erythropoiesis and anemia. Finally, other possible mechanisms include a reduction in inflammatory markers, fibrosis, podocyte injury, and other related mechanisms. SGLT2i have shown significant and highly consistent benefits in renal and cardiovascular protection. The complexity and interconnectedness of the primary and secondary mechanisms of action make them a most interesting and exciting pharmacologic group.<\/jats:p>","DOI":"10.3389\/fmed.2021.777861","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T05:10:17Z","timestamp":1639977017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":259,"title":["Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review"],"prefix":"10.3389","volume":"8","author":[{"given":"Jorge I.","family":"Fonseca-Correa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","article-title":"Active sugar transport in health and disease","volume":"261","author":"Wright","year":"2007","journal-title":"J Intern Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"Defronzo","year":"2013","journal-title":"Diabetes Care."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes."},{"key":"B8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2 online mendelian inheritance in man","volume":"1","author":"Ghezzi","year":"2018","journal-title":"Diabetologia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissues sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/meta.2000.7729","article-title":"T-1095, A renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats","volume":"49","author":"Adachi","year":"2000","journal-title":"Metabolism."},{"key":"B13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1055\/s-2002-26714","article-title":"Normalization of cytoplasmic calcium response in pancreatic \u03b2-cells of spontaneously diabetic GK rat by the treatment with T-1095, a specific inhibitor of renal Na+-glucose co-transporters","volume":"34","author":"Yasuda","year":"2002","journal-title":"Horm Metab Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"2021","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes."},{"key":"B24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes, Obes Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI115031","article-title":"Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression","volume":"87","author":"Kahn","year":"1991","journal-title":"J Clin Invest."},{"key":"B28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapaglif lozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"B32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Original Article : Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes, Obes Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"\u0160krti\u0107","year":"2014","journal-title":"Diabetologia."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia."},{"key":"B35","doi-asserted-by":"publisher","first-page":"98720","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI insight."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.3390\/ijms21082987","article-title":"SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db\/db mice, a model of type 2 diabetes","volume":"21","author":"Korbut","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013Glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis despoina","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs."},{"key":"B41","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"12","author":"Abdul-Ghani","year":"2012","journal-title":"Curr Diab Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2021","volume":"44","author":"Care","year":"2021","journal-title":"Diabetes Care."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Ren Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","article-title":"Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition","volume":"308","author":"Layton","year":"2015","journal-title":"Am J Physiol Ren Physiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Ren Physiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am J Physiol Ren Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Stef\u00e1nsson B","year":"2020","journal-title":"J Diabetes Complications."},{"key":"B50","doi-asserted-by":"publisher","first-page":"E1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J Cell Physiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"9944880","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF- \u03ba B, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J Immunol Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jdi.12802","article-title":"Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet","volume":"9","author":"Takagi","year":"2018","journal-title":"J Diabetes Investig."},{"key":"B56","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22105089","article-title":"Empagliflozin inhibits il-1\u03b2-mediated inflammatory response in human proximal tubular cells","volume":"22","author":"Pirklbauer","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"2021","author":"McMurray","year":"2021","journal-title":"Circulation."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"B64","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3803\/EnM.2021.987","article-title":"Cardiorenal protection in diabetic kidney disease","volume":"36","author":"Lee","year":"2021","journal-title":"Endocrinol Metab."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.777861\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T05:10:20Z","timestamp":1639977020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.777861\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":64,"alternative-id":["10.3389\/fmed.2021.777861"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.777861","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"article-number":"777861"}}